Simultaneous tumors: ovarian cancer in a patient with multiple myeloma

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Multiple myeloma is the second most common hematological malignancy, accounting for approximately 1% and 10–15% of malignant tumors of the hematopoietic and lymphoid systems, respectively. Until recently, the diagnosis of multiple myeloma was inherently associated with unfavorable prognosis of overall survival. On the one hand, advanced diagnosis techniques and the development of new treatment approaches have led to the improved life expectancy and significant reduction of mortality of patients with multiple myeloma. On the other hand, the medical and research communities have encountered a previously unknown issue: the combination of multiple myeloma with other types of cancer. This combination sets a task of multidisciplinary approach in the diagnosis and requires development of patient management strategy and prognostic parameters of the outcome. Some researchers adhere to the theory of independent tumor appearance in patients suffering from multiple myeloma, while other authors suppose that multiple myeloma and secondary cancer virtually represent multiple primary malignant neoplasms. This article presents a clinical case of postmortem verification of ovarian cancer in a patient with recurrent multiple myeloma.

About the authors

Igor Yu. Gadaev

I.M. Sechenov First Moscow State Medical University

Email: doctor-gai@yandex.ru
ORCID iD: 0000-0002-2782-4179

MD, Cand. Sci. (Medicine), Assistant Professor

Russian Federation, Moscow

Irina V. Gadaeva

I.M. Sechenov First Moscow State Medical University

Email: gadaeva-gin@gmail.com
ORCID iD: 0000-0003-0144-4984

MD, Cand. Sci. (Medicine), Assistant Professor

Russian Federation, Moscow

Kseniya A. Rossolovskaya

I.M. Sechenov First Moscow State Medical University

Author for correspondence.
Email: dr.rossolovskaya@yandex.ru
ORCID iD: 0000-0002-7026-1607
SPIN-code: 4432-5748

Graduate Student

Russian Federation, Moscow

Olga V. Bochkarnikova

I.M. Sechenov First Moscow State Medical University

Email: ovbochkarnikova@mail.ru
ORCID iD: 0000-0001-9316-6920

Gematologist, Head of hematology

Russian Federation, Moscow

Irina Ya. Sokolova

I.M. Sechenov First Moscow State Medical University

Email: irinasokol64@mail.ru
ORCID iD: 0000-0002-8884-1087

Hematologist

Russian Federation, Moscow

References

  1. Kaprin AD, Starinsky VV, Petrova GV, editors. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Moscow: P.A. Herzen Moscow State Medical Research Institute — branch of the Federal State Budgetary Institution “NMIC of Radiology” of the Ministry of Health of the Russian Federation; 2018. (In Russ.)
  2. Dong HH, Li J, Kang L, et al. Simultaneous multiple myeloma and non-small cell lung carcinoma: A case report and review of the literature. Oncol Lett. 2022;23(6):195. doi: 10.3892/ol.2022.13315
  3. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi: 10.1038/s41375-022-01620-2
  4. Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011;183:25–35. doi: 10.1007/978-3-540-85772-3_2
  5. Raluy M, Ramagopalan S, Panjabi S, Lambrelli D. Epidemiology and clinical characteristics of patients with multiple myeloma in the United Kingdom. Blood. 2014;124(21):2048. doi: 10.1182/blood.V124.21.2048.2048
  6. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548–567. doi: 10.1002/ajh.25791
  7. Liu R, Gao Q, Foltz SM, et al. Co-evolution of tumor and immune cells during progression of multiple myeloma. Nat Commun. 2021;12(1):2559. doi: 10.1038/s41467-021-22804-x
  8. Sant M, Minicozzi P, Mounier M, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15(9):931–942. doi: 10.1016/S1470-2045(14)70282-7
  9. Kaiser MF, Croft J, Shah P, et al. Durable response of multiple myeloma and non-small cell lung cancer with simultaneous, biologically targeted treatment. Br J Haematol. 2020;189(1):e1–3. doi: 10.1111/bjh.16393
  10. Jones JR, Cairns DA, Gregory WM, et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J. 2016;6(12):e506. doi: 10.1038/bcj.2016.114
  11. Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med. 1970;283(21):1121–1125. doi: 10.1056/NEJM197011192832101
  12. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer Journal for Clinicians. 2019;69(1):7–34. doi: 10.3322/caac.21551
  13. Wang Y, Li F, Luo J, et al. Testicular plasmacytoma: a case report and review of the literature. Chin Med J. 2008;121(10):956–958.
  14. Morariu I, Burns P, Roche P, Hone S. Triple manifestation of extramedullary plasmacytoma in the upper airway: an unusual clinical entity. J Laryngol Otol. 2011;125(9):970–972. doi: 10.1017/s0022215111001046
  15. Varettoni M, Corso A, Pica G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21(2):325–330. doi: 10.1093/annonc/mdp329
  16. Gagelmann N, Eikema D, Iacobelli S, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica. 2018;103(5):890–897. doi: 10.3324/haematol.2017.178434
  17. Mirandola L, Nguyen DD, Rahman RL, et al. Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer? Int Rev Immunol. 2014;33(5):417–27. doi: 10.3109/08830185.2014.911855
  18. Landgren O, Thomas A, Mailankody S. Myeloma and second primary cancers. N Engl J Med. 2011;365(23):2241–2242. doi: 10.1056/NEJMc1111010
  19. Schor APT, Moraes MPT, Bisson FW, et al. Primary plasmacytoma of the cervix in a 21-year-old female patient. Int J Gynecol Pathol. 2010;29(3):290–293. doi: 10.1097/PGP.0b013e3181c070b4
  20. Curtis RE, Freedman DM, Ron E, et al., editors. New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute, NIH Publ. No. 05-5302. Bethesda, MD, 2006.
  21. Hideshima T, Mitsiades C, Tonon G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7(8):585–598. doi: 10.1038/nrc2189
  22. Osserman EF, Takatsuki K, Talal N. Multiple myeloma I. the pathogenesis of ‘amyloidosis’. Semin Hematol. 1964;1:3–85.
  23. Mailankody S, Pfeiffer RM, Kristinsson SY, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes following multiple myeloma and its precursor disease (MGUS). Blood. 2011;118(15):4086–4092. doi: 10.1182/blood-2011-05-355743
  24. Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship — genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst. 2006;98(1):15–25. doi: 10.1093/jnci/djj001

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).